Immunoassay heterogeneity iyo saamaynta ay ku leedahay ilaalinta SARS-CoV-2

Serosurveillance waxa ay wax ka qabtaa qiyaasida baahsanaanta unugyada difaaca jirka ee dadka ka dhanka ah cudur-sidaha gaarka ah.Waxay ka caawisaa cabbiraadda difaaca dadwaynaha ka dib caabuqa ama tallaalka waxayna leedahay utility epidemiological ee cabbiraadda khatarta gudbinta iyo heerarka difaaca dadweynaha.Cudurka coronavirus ee hadda jira 2019 (COVID-19) faafa, serosurvey ayaa door muhiim ah ka ciyaartay qiimeynta heerka dhabta ah ee cudurka daran ee neef-mareenka ee coronavirus 2 (SARS-CoV-2) ee dadka kala duwan.Waxa kale oo ay gacan ka gaysatay samaynta tilmaamayaasha cudurrada faafa, tusaale ahaan, saamiga dhimashada caabuqa (IFR).

Dhammaadkii 2020, 400 serosurvey ayaa la daabacay.Daraasadahaani waxay ku saleysan yihiin noocyo kala duwan oo tallaal-is-difaac ah kuwaas oo loogu talagalay in lagu falanqeeyo unugyada difaaca jirka ee ka dhanka ah SARS-CoV-2, ugu horreyntii lagu beegsanayo dhammaan ama qayb ka mid ah borotiinnada (S) iyo nucleocapsid (N) borotiinnada SARS-CoV-2.Xaaladda hadda jirta ee COVID-19, mowjado faafa oo isdaba joog ah ayaa ka dhacayay gobollo kala duwan oo adduunka ah, kuwaas oo saameeyay isku dhafka dadweynaha ee kala duwan waqti go'an.Dhacdadani waxay caqabad ku noqotay la socodka SARS-CoV-2 iyada oo ay ugu wacan tahay muuqaal-difaac oo sii kordhaysa.

Saynis yahanadu waxay arkeen in heerarka anti-SARS-CoV-2 ee ka hortagga unugyada ay u janjeeraan inay qudhunaan ka dib muddada nasashada.Dhacdooyinka noocan oo kale ah waxay kordhiyaan fursadaha natiijooyinka xun ee immunoassays.Waxyeellooyinkan been abuurka ah waxay si sax ah u wiiqi karaan darnaanta heerka caabuqa dhabta ah haddii aan la aqoonsan oo si degdeg ah loo saxin.Intaa waxaa dheer, kinetics-ka kahortagga caabuqa ka dib waxay u muuqdaan si kala duwan si waafaqsan darnaanta caabuqa - caabuqa COVID-19 ee aad u daran wuxuu u janjeeraa inuu keeno koror weyn oo ah heerka unugyada difaaca jirka marka loo eego caabuqyada fudud ama asymptomatic.

Daraasado dhowr ah ayaa lagu tilmaamay kinetics antibody lix bilood ka dib caabuqa.Daraasadahaani waxay ogaadeen in badi shakhsiyaadka bulshooyinka uu ku dhacay SARS-CoV-2 ay muujiyeen caabuqyo fudud ama asymptomatic.Cilmi-baarayaashu waxay rumeysan yihiin inay lama huraan tahay in la qiyaaso isbeddelka heerarka unugyada difaaca jirka, iyadoo la adeegsanayo immunoassays la heli karo, dhammaan noocyada kala duwan ee darnaanta caabuqa.Da'da ayaa sidoo kale loo tixgeliyey inay tahay arrin muhiim ah daraasaddan.

Daraasad dhowaan la sameeyay, saynisyahannadu waxay qiyaaseen heerarka anti-SARS-CoV-2 antibody ilaa 9 bilood ka dib caabuqa, waxayna ku daabaceen natiijooyinkoodamedRxiv* server-ka preprint.Daraasadda hadda jirta, koox ka kooban shakhsiyaad seropositive ah ayaa lagu shaqaaleysiiyay baaritaanno lagu sameeyay Geneva, Switzerland.Cilmi-baadhayaashu waxay adeegsadeen saddex immunoassays oo kala duwan, kuwaas oo ah, anti-S1 ELISA oo ogaanaya IgG (oo loo yaqaan EI), tirada Elecsys anti-RBD (oo loo yaqaan, Roche-S) iyo Elecsys anti-N semiquantitative (oo loo yaqaan Roche- N).Cilmi-baarista hadda waxay bixisaa aragti muhiim ah oo ku saabsan daraasadaha serologic-ku-saleysan dadweynaha waxayna muujineysaa kakanaanta muuqaalka difaaca jirka taasoo ay ugu wacan tahay isku-darka caabuqyada COVID-19 ee dhow iyo kuwa fog, iyo sidoo kale tallaalka.

Daraasadda iyadoo la tixgelinayo ayaa sheegtay in shakhsiyaadka uu ku dhacay COVID-19 oo leh astaamo fudud ama asymptomatic, ay daaha ka qaadeen jiritaanka unugyada difaaca jirka.Unugyadan ayaa bartilmaameedsaday midkood nucleocapsid (N) ama borotiinada spike (S) ee SARS-CoV-2 waxaana la ogaaday inay sii jiraan ugu yaraan 8 bilood ka dib caabuqa.Si kastaba ha ahaatee, ogaanshahooda ayaa aad ugu xiran doorashada tallaalka difaaca jirka.Cilmi-baarayaashu waxay ogaadeen in cabbirada bilowga ah ee unugyada difaaca jirka, ee laga soo qaatay ka qaybgalayaasha afar bilood iyo badh gudahooda ee COVID-19, ay ahaayeen kuwo joogto ah dhammaan saddexda nooc ee immunoassays ee loo adeegsaday daraasaddan.Si kastaba ha ahaatee, afartii bilood ee hore ka dib, iyo ilaa siddeed bilood ka dib caabuqa, natiijadu way kala duwanaatay imtixaanada.

Cilmi-baadhistan ayaa shaaca ka qaaday in kiiska EI IgG assay, mid ka mid ah afartii ka qaybgalayaashu uu dib u soo noqday.Si kastaba ha noqotee, immunoassays kale, sida Roche anti-N iyo ka-hortagga RBD wadarta imtixaannada Ig, wax yar ama wax-ka-noqosho ah ayaa la ogaaday isla muunaddaas.Xataa ka qaybgalayaasha qaba caabuqyada fudud, kuwaas oo markii hore loo malaynayay inay ka jawaab celinayaan difaac yar, waxay muujiyeen dareen iyaga oo isticmaalaya ka-hortagga RBD iyo ka-hortagga N-ka-hortagga imtixaannada Ig Roche.Labada baaritaanba waxay ahaayeen kuwo xasaasi ah in ka badan 8 bilood caabuqa ka dib.Sidaa darteed, natiijooyinkani waxay daaha ka qaadeen in labadaba Roche immunoassays ay aad ugu habboon yihiin in la qiyaaso seroprevalence ka dib waqti dheer ka dib caabuqa bilowga ah.

Intaa ka dib, iyada oo la adeegsanayo falanqaynta jilitaanka, cilmi-baarayaashu waxay soo gabagabeeyeen in la'aanteed habka cabbirka saxda ah, gaar ahaan, tixgelinta dareenka kala duwan ee waqtiga, sahaminta seroprevalence ma noqon doonto mid sax ah.Tani waxay horseedi doontaa in la dhayalsado tirada dhabta ah ee caabuqyada isbiirsaday ee dadweynaha.Daraasaddan immunoassay waxay muujisay jiritaanka kala duwanaanshaha heerarka seropositivity ee u dhexeeya imtixaannada ganacsi ahaan la heli karo.

Waa in la ogaadaa inay jiraan dhowr xaddidaad oo daraasaddan ah.Tusaale ahaan, reagent-ka la isticmaalay marka la samaynayo qiimaynta EI ee labada gundhig (imtixaanka hore ama 1aad) iyo dabagalka (imtixaanka 2aad ee isla musharixiinta) muunado wakhti cayiman gudahooda way kala duwanaayeen.Xaddidaadda kale ee daraasaddan ayaa ah in kooxuhu aysan ku jirin carruur.Ilaa hadda, wax caddayn ah oo dhaqdhaqaaqa lidka-jirka ee muddada-dheer ee carruurta lama diiwaangelin.


Waqtiga boostada: Mar-24-2021